Company intelligence / Profile preview

Corbus Pharmaceuticals Holdings, Inc.

Norwood, Massachusetts, United Statescorbuspharma.com ↗

Ownership: Public · CRBP
Development stage: Phase 1

Overview

Corbus has completed enrollment of the dose escalation part of its Phase 1 clinical trial for CRB-701 with data expected in Q1 2025. The company also dosed the first patient in a Phase 1 clinical study of CRB-913 for obesity treatment in March 2025.

Therapeutic areas: PulmonologyRheumatologyEndocrinologyImmunologyOncology
Modalities: Antibody Drug Conjugate (ADC)Monoclonal antibodiesCannabinoid receptor agonistsCB1 Inverse Agonist
Industry: Biotech

Drug pipeline

7 assets

lenabasum

6 more assets in the full pipeline.

Request access →

Partnerships

CSPC Pharmaceutical Group

Financials

Market cap: $152.7M
Total revenue: $0
Enterprise value: $39M

Beyond the preview

Go deeper on Corbus Pharmaceuticals Holdings, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corbus Pharmaceuticals Holdings, Inc..

Explore the full profile